Business Wire

CGTN

10.3.2021 14:26:12 CET | Business Wire | Press release

Share
CGTN: UK Regulator Criticized for 'Act of Censorship' by Banning CGTN

Britain's communications regulator Ofcom has been criticized for its decision to ban and fine China Global Television Network (CGTN) for political reasons.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210310005537/en/

A group of journalists, filmmakers and artists recently challenged Ofcom's "act of censorship" in an open letter published by the No Cold War campaign and the Morning Star.

"The decision by Ofcom to remove the broadcasting license of CGTN is an act of censorship which is not in the interests of Britain and its people," the open letter said, calling the move an "attack on free speech."

Ofcom revoked the license of CGTN to broadcast in the UK in early February on the grounds of its ultimate control and its political attributes. Beijing slammed the move as political repression against Chinese media.

In their letter, the signatories questioned Ofcom's justification for banning CGTN.

"Ofcom's justification for taking CGTN off air is that any holder of a broadcasting license in Britain must not be controlled by political bodies. However, this law is only selectively applied. Numerous private and state channels have clear political agendas or control – the BBC itself, for example, which had its staff vetted by MI5, has not had its broadcasting license revoked," it said.

The letter urged Ofcom to reverse its decision and reinstate CGTN's license.

CGTN committed to balanced reporting

A spokesperson for CGTN on Tuesday called on the British regulator to calmly listen to the opinions expressed in the letter and end its political crackdown on Chinese media.

The spokesperson said that as an international news channel, CGTN is committed to providing "accurate, timely and objective news and information with diverse and balanced views" for its global audiences.

"China is increasingly connected and engaged with the rest of the world including the UK," the spokesperson said in a statement. "It is our responsibility to present Chinese viewpoints and perspectives in our news reporting, which is what our viewers expect and is also in the interest of the public."

'The world should be able to hear China's voice'

In a separate statement on Tuesday, CGTN said it is disappointed with and firmly opposes Ofcom's latest sanction decisions and adjudications against it.

Ofcom on Monday fined CGTN 225,000 British pounds (about $310,933) for "breaching rules on fairness, privacy and due impartiality" just weeks after it stripped the network of its right to air in Britain.

"CGTN believes its coverage of the 2019 violent protests in the Hong Kong Special Administrative Region was fair, truthful and duly impartial," the statement said.

"As a news outlet from China, CGTN made it possible for global audiences to see and hear a more complete picture of events in Hong Kong by reporting on the voices opposing violence and destruction," it stressed. "The fact that CGTN has been sanctioned by Ofcom for its objective coverage of the event is unjust."

"It is in the public interest that the world should be able to hear China's voice and perspective and see the true picture more clearly," it added.

At a regular press briefing on Tuesday, Chinese Foreign Ministry spokesperson Zhao Lijian urged Ofcom and certain individuals to immediately cease engaging in political manipulation and correct their mistakes, slamming the move as "blatant political oppression."

https://news.cgtn.com/news/2021-03-10/UK-regulator-criticized-for-act-of-censorship-by-banning-CGTN-YvNehReHaE/index.html

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SLB to Acquire Kelvion, Expanding its Role Across Data Center Infrastructure31.8.2026 12:50:00 CEST | Press release

Scalable, energy-efficient and reliable thermal management technologies will optimize operating performance in increasingly complex data centers and industrial systems SLB (NYSE: SLB) today announced it has signed an agreement to acquire Kelvion, a global provider of thermal management and heat exchange technologies. The acquisition strengthens SLB's Data Center Solutions business with critical thermal management technologies and expands the company's role in data center infrastructure, which is one of the world’s fastest-growing industrial and technology markets. “AI is driving the most significant infrastructure investment cycle in our lifetime,” said Olivier Le Peuch, chief executive officer of SLB. “This transaction accelerates our ambition to become an industrial technology partner to the data center industry and help customers address the growing infrastructure complexity required to scale AI. Kelvion advances our path toward more integrated data center infrastructure solutions,

BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer31.8.2026 12:00:00 CEST | Press release

Findings provide further evidence of overall survival benefit of TEVIMBRA plus ZIIHERA and chemotherapy regimen in HER2+ GEAZIIHERA plus chemotherapy demonstrated statistically significant overall survival benefit at second interim analysis of HERIZON-GEA-01 trial BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the second interim analysis (IA2) of the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), in combination with chemotherapy, with and without TEVIMBRA® (tislelizumab), as first-line treatment for HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). At IA2, ZIIHERA plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared with trastuzumab plus chemotherapy, meeting the remaining primary endpoint analysis of the study. IA2 also provided longer follow-up data for the TEVIMBRA plus ZIIHERA

GigaDevice Strengthens EMEA and Southeast Asia Market Reach Through Strategic Partnership with Rutronik31.8.2026 09:00:00 CEST | Press release

GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, today announced a new strategic franchise partnership with Rutronik Elektronische Bauelemente GmbH, one of Europe’s leading broadline distributors of electronic components. The agreement covers EMEA and Southeast Asia, including India, and provides customers with broader access to GigaDevice’s comprehensive portfolio of microcontrollers, sensors, and power management solutions. The partnership further strengthens GigaDevice’s distribution network and local market presence across key regions. With its strong presence across Europe and growing coverage in Southeast Asia, Rutronik provides GigaDevice with an established channel supported by extensive market reach, technical expertise, and customer relationships. The collaboration will help expand access to GigaDevice’s embedded solutions across a broad range of applications and industries, including indus

Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 14:23:00 CEST | Press release

–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline ––Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM ––Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes ––New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR)

New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release

Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye